Abstract: This prospective study evaluated the 95% effective dose (ED 95 ) of nalbuphine in inhibiting body movement during outpatient-induced abortion and its clinical efficacy versus the equivalent of sufentanil. The study was divided into two parts. For the first part, voluntary first-trimester patients who needed induced abortions were recruited to measure the ED 95 of nalbuphine in inhibiting body movement during induced abortion using the sequential method (the Dixon up-and-down method). In the second part, this was a double-blind, randomized study. Sixty cases of first-trimester patients were recruited and were randomly divided into two groups (n = 30), including group N (nalbuphine at the ED 95 dose) and group S (sufentanil at an equivalent dose). Propofol was given to both groups as the sedative. The circulation, respiration and body movement of the two groups in surgery were observed. The amount of propofol, the awakening time, the time to leave the hospital and the analgesic effect were recorded. The ED 95 of nalbuphine in inhibiting body movement during painless surgical abortion was 0.128 mg/kg (95% confidence intervals 0.098-0.483 mg/kg). Both nalbuphine and the equivalent dose of sufentanil provided a good intraoperative and post-operative analgesic effect in outpatient-induced abortion. However, the post-operative morbidity of dizziness for nalbuphine was less than for sufentanil (p < 0.05), and the awakening time and the time to leave the hospital were significantly shorter than those of sufentanil (p < 0.05). Nalbuphine at 0.128 mg/kg was used in outpatient-induced abortion as an intraoperative and post-operative analgesic and showed a better effect compared with sufentanil.
The surgical abortion procedure commonly causes an experience of discomfort to women. Sedative drugs, with a combination of analgesics, are usually used to lessen the pain and anxiety and to support surgical success. Partially because of its rapid recovery profile, propofol is the most frequently used intravenous anaesthetic today and has achieved widespread use in outpatient surgery [1] . Opioid l receptor agonists, such as sufentanil or fentanyl [2, 3] , are the main analgesics used. Although the period of outpatient-induced abortion is usually very short, patients do not leave the hospital until dizziness and pain are absent. The anaesthesia strategies still need improvement.
The uterus is mainly innervated by the sympathetic and parasympathetic nervous systems, which come from the spinal cord. Some j receptor agonists, such as nalbuphine, will concentrate in the spinal cord and cause rapid onset, long duration, mild respiratory depression and haemodynamic stability, which may be suitable for intraoperative and post-operative analgesics in outpatient-induced abortion. There are few reports about nalbuphine used in induced abortion.
In this study, we evaluated the 95% effective dose (ED 95 ) of nalbuphine for outpatient-induced abortion by the sequential method and compared the equivalent dose of sufentanil to determine the feasibility and superiority of nalbuphine in outpatient-induced abortion.
Materials and Methods
Patients. This clinical study was approved by the Hospital Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and was registered in the clinical trial registration centre of China (ChiCTR-IOR-17011263). Written informed consent was obtained from all patients.
The inclusion criteria were American Society of Anesthesiologists (ASA) physical status I-II female patients aged 18-44 years scheduled for an outpatient-induced abortion and requiring general anaesthesia, foetal age <10 weeks, primipara or never had a vaginal delivery, no preoperative medications and an operation time within 10 min. The exclusion criteria included hepatitis and renal failure, habitual sedative or analgesic use, mental illness and allergy to nalbuphine, sufentanil or propofol.
The study was divided into two parts: determination of the ED 95 of nalbuphine and comparison with sufentanil.
ED 95 of nalbuphine. Anaesthesia methods. All the patients were fasting from solids for 8 hr and liquids for 2 hr before the operation. Intravenous access was established, and the anaesthesia machine was inspected. Standard monitoring was instituted before the induction of anaesthesia in the outpatient operating room, including ECG, non-invasive blood Authors for correspondence: Xuzhong Xu, Department of Anesthesiology, The First Affiliated Hospital, Wenzhou Medical University, Shangcai village, Nanbaixiang town, Ouhai District, Wenzhou City 325000, Zhejiang Province, China (e-mail xuzhong@263.net). and Beibei Shi, Department of gynecology, the First Affiliated Hospital, Wenzhou Medical University, Shangcai village, Nanbaixiang town, Ouhai District, Wenzhou City 325000, Zhejiang Province, China (e-mail 18864228@qq.com). pressure (BP) and oxygen saturation (SpO 2 ). Then, the patients were set in the lithotomy position, with skin preparation and draping. All the patients were supported with 3 L/min. of nasal catheter oxygen inhalation and were asked to hold the facial mask by themselves.
Next, nalbuphine (Batch number: 1169401; Yichang Renfu Pharmaceutical Co., Ltd. Yichang, Hubei province, China) was administered intravenously. Given the onset time of nalbuphine is 3 min., we waited for 3 min. After 3 min., propofol (Batch number: 16KK5526 Fresenius Kabi Pharmaceutical Co., Ltd., Bad Homburg v.d.H., Germany) was administered intravenously at a constant speed until the patient lost consciousness and dropped the hand-held mask; then the surgery began (surgery by the same gynaecologist). If the patient showed body movement during the operation, additional propofol, at 0.5-1 mg/kg, was administered. Once the SpO 2 fell to 90%, assisted ventilation by a facial mask with oxygen was applied. If the mean arterial pressure (MAP) was <50 mmHg, ephedrine was administered. If the heart rate (HR) was <45 beats/min., atropine was administered. After surgery and recovery, the patients were transported to the recovery room to rest. If the patients were dizzy in sitting position, then they continued by lying down. If patients had frequent vomiting, then ondansetron was administered to stop the vomiting.
Dixon up-and-down method. The dose of nalbuphine to each patient was determined by the Dixon up-and-down method [4] . According to geometric progression, the dose gradient was divided into 10 steps, that is, 0.173, 0.144, 0.120, 0.100, 0.083, 0.069, 0.058, 0.040 and 0.033 mg/kg. The ED 95 of nalbuphine in inhibiting body movement during outpatient-induced abortion, which was calculated in pre-test, was 0.144 mg/kg. Thus, the initial patient received a prescription dose of 0.144 mg/kg. A valid inhibition of body movement was defined as without any body movement. In contrast, an invalid inhibition of body was defined as body movement that appeared during the surgery. If the inhibition of body movement during surgery was effective, the next patient would receive a decreased dose grade. If the inhibition of body movement was invalid, the next patient received an increased dose grade. This process was repeated until there were nine crossover pairs [5, 6] (i.e. a successful no body movement, followed by a failure of having body movement).
Comparison with sufentanil.
Groups. Sixty cases of first-trimester patients were recruited. The patients were randomly divided into two groups, including the nalbuphine group (group N, n = 30) and the sufentanil group (group S, n = 30).
Anaesthesia methods. The preoperative preparation and anaesthesia methods were the same as in the first part. The patients were grouped according to the envelope method. The dose of the ED 95 (0.128 mg/kg) of nalbuphine, which was achieved in the first part, was administered intravenously at a low speed in group N. The equivalent dose of sufentanil [7, 8] (0.128 lg/kg) was administered in group S.
Efficacy measurements and variables. The demographic and medical data, including the subject's age, body mass index (BMI), gestational age (week), dysmenorrhoea and the use of cervical dilating rods, were collected. The HR, BP, SpO 2 and respiratory rate (RR) were measured before anaesthesia induction and throughout the operation and recovery period.
The number of cases that showed body movement during the surgery and the amount of propofol were recorded. The time of surgery, the awakening time (the time between the end of the surgery and when the patients responded to the call) and the time to leave the hospital (the time between waking up and when the patients left the hospital) were recorded. The standard for leaving the hospital is our new outpatient operation standard (vital signs, pain, orientation, dizziness and walking; Table 1 ). The criterion used for patient discharge was a total score of ≥8. Additionally, the score of the visual analogue scale (VAS) was evaluated and recorded at 15 min., 30 min., 1 hr, 2 hr and 3 hr after awakening.
The number of patients with dizziness and nausea/vomiting after awakening was also recorded. Respiratory depression (RR <10 beats/ min. or SpO 2 <90% during inhaling oxygen) and circulatory depression (MAP <50 mmHg or HR <45 beats/min.) during surgery and other complications were recorded.
Statistical analysis. SPSS statistical software (IBM Corporation, version 19 Armonk, New York, USA) was used for the statistical analyses. The median effective dose (ED 50 ) and ED 95 and the 95% confidence intervals (CI) of nalbuphine were determined by binary regression (probit) [9] .
The sample size of part two was evaluated by PASS 11.0 (Power Analysis and Sample Size; NCSS, LLC., Englewood, NJ, USA). The main indicator was the time to leave the hospital. The preexperiment had five cases in each group. The mean AE standard deviation of Group N and Group S was 33.0 AE 3.03 and 41.0 AE 11.45, respectively. A sample size of 25 in each group was determined to be required for a b value of 0.10 and an a value of 0.05. Taking into consideration the data lost and patients who could not be interviewed after surgery, we selected 30 patients in each group as the sample size to ensure that the experiment had a large enough sample size.
Normally distributed statistics were analysed with the Mean AE standard deviation ( X AE s), and a two independent sample t-test was used to evaluate the differences between the two groups in this condition. The nonparametric data were further analysed using the median (Q1, Q3) or ratio, and a nonparametric test was used to evaluate the differences between the two groups in this condition. Dysmenorrhoea, the use of cervical dilating rods and dizziness were compared by chisquare test. The awakening time (non-normally distributed data) and VAS scores were compared by the Mann-Whitney U-test. Finally, p values < 0.05 were accepted as statistically significant.
Results
Forty-four patients were enrolled in the first part of the study. The individual responses to nalbuphine using Dixon's up-and- The criterion used for patient discharge was a total score of ≥8.
down method are shown in fig. 1 . The ED 50 of nalbuphine in inhibiting body movement during outpatient-induced abortion was 0.068 mg/kg (50% CI, 0.053-0.082 mg/kg) and the ED 95 was 0.128 mg/kg (95% CI, 0.098-0.483 mg/kg). No significant respiratory depression, circulatory depression or vomiting occurred during the operation. The characteristics of the enrolled subjects in the second part of the study are shown in Table 2 . A total of 60 subjects were recruited and completed the study, and their data were analysed to produce the final results (n = 30 per group). There were no significant differences in age, height, weight, BMI, dysmenorrhoea and the use of cervical dilating rods among the patients in the two groups (p > 0.05).
The VAS score of the two groups -15 min., 30 min., 1 hr, 2 hr and 3 hr after the awaken time -is shown in Table 3 . As shown in the table, the analgesic effects of the two groups at 15 min., 30 min. and 1 hr after surgery were fine, and the difference was not statistically significant (p > 0.05). The VAS score of nalbuphine was less than that of sufentanil at 2 and 3 hr after surgery, and the difference was statistically significant (p < 0.05).
There was no statistically significant difference in propofol dosage and the surgery time between the two groups (p > 0.05). However, the awakening time and the time to leave the hospital for group N were significantly shorter than for group S (p < 0.05). The incidence of dizziness in group N was significantly less than in group S (10% versus 33%), and the difference was statistically significant (p < 0.05), as shown in Table 4 .
In group N, two cases showed body movement, whereas three cases in group S did this, and the difference between the two groups was not statistically significant. Two cases had respiration depression in group S, and there were no statistically significant differences between the two groups. There was no circulatory inhibition, nausea or vomiting in both groups.
Discussion
There are limited studies on the use of nalbuphine in induced abortion, and the effective dose of nalbuphine is not clear. At the present time, the methods used to calculate the ED 50 are Karber's method, a simple probability unit method, a regression method, a sequential method, etc. The sequential method serves the purpose of evaluating the efficacy of drugs with fewer cases, but the outcome must be assessed within a short time frame, and it is used normally in the anaesthesia study design [9] . Therefore, in the first part of our study, the main criterion was whether the body movement was inhibited, and Normally distributed statistics data were mean AE S.D., and a two independent sample t-test was used to evaluate the differences between the two groups. Dysmenorrhoea and the use of cervical dilating rods were given in ratio and were compared by chi-square test. There were no significant differences in the two groups (p > 0.05). Table 3 . Comparison of the VAS score of two groups at each time-point after awakening time.
VAS
Group N Groups S we measured the ED 50 and ED 95 and 95% CI of nalbuphine by the sequential method. The ED 50 of nalbuphine in inhibiting body movement during painless surgical abortion was 0.068 mg/kg (50% CI 0.053-0.082 mg/kg), and the ED 95 was 0.128 mg/kg (95% CI 0.098-0.483 mg/kg). Ahsan-ul-Haq M reported that nalbuphine, at 0.2 mg/kg, prevented a marked rise in HR and the mean arterial pressure associated with laryngoscopy and orotracheal intubation [10] . Peyrol et al. [11] reported that the average dose of nalbuphine was 0.27 AE 0.05 mg/kg when combined with midazolam to offer sedation and analgesia for subcutaneous implantable cardioverter defibrillator (S-ICD) implantation, which was significantly higher than our dosage. The reason for this may be that the analgesic demand of S-ICD is higher than for surgical abortion. On the other hand, it also suggests that our dose is safe. Although the surgery time for abortion is short, it has a great impact on the patient's physical and mental health. At the same time, post-operative uterine contraction pain also seriously affects the resting quality of patients after surgery, and more and more patients choose painless surgical abortion [12] . The anaesthesia of surgical abortion requires a shorter onset time, adequate sedative and analgesia, quicker recovery time after surgery and less side effects. The uterus is innervated by the sympathetic and parasympathetic system, and the pain caused by abortion is visceral pain. At the present time, induced abortion often uses propofol with a combination of opioid analgesics [1, 2] . The classical opioid receptors are divided into three regions, including l, j and d, and are distributed in the conducted pain zone and areas related to mood and behaviour. They are concentrated in the aqueductal grey matter, medial thalamus, amygdala and spinal glial. These complex receptors are activated by different agonists, producing different biological effects. The activation of the l receptor in the brain stem produces analgesia above the spinal cord, causing respiratory depression, less gastrointestinal motility, nausea and vomiting, a reduction in HR and drug dependence, and the representative drugs are morphine and sufentanil. Drugs activating the j receptors produce spinal cord analgesia, sedation and mild respiratory depression, and the representative drugs are dezocine and nalbuphine. Nalbuphine was used in this study and is a j receptor agonist with a high concentration in the spinal cord, producing mild respiratory depression, haemodynamic stability, a rapid onset and duration up to 4-6 hr, and is widely used in the clinic. The results of this study showed that sufentanil and nalbuphine effectively alleviated the post-operative uterine contraction pain at 15 min., 30 min. and 1 hr after surgery, and the analgesic effect of the two groups was equivalent. However, 2 and 3 hr after surgery, the effect of pain relief of nalbuphine was better than that of sufentanil.
Nalbuphine, as an opioid receptor agonist-antagonist, activates the j receptor and partially antagonizes the l receptor.
In the results of this study, the patients who received nalbuphine left the hospital earlier than the patients who received sufentanil. This may be due to the low incidence of dizziness in the patients administered nalbuphine. To a certain extent, dizziness extends the patient's hospital stay. The low incidence of dizziness in the patients who received nalbuphine may be related to nalbuphine concentrated in the spinal cord and sufentanil in the brain stem.
The limitations of this study include the ambiguous reason for dizziness and having no serum nalbuphine/sufentanil assays.
In summary, the ED 95 of nalbuphine in inhibiting body movement during outpatient artificial abortion was 0.128 mg/ kg, and nalbuphine combined with propofol for outpatientinduced abortion was a good strategy. Normally distributed statistics data were mean AE S.D., and a two independent sample t-test was used to evaluate the differences. The awakening time (non-normally distributed data) was the median (Q1, Q3). The awakening time was compared by the Mann-Whitney U-test. Dizziness was given in ratio and was compared by chi-square test.
Compared with group N, *p = 0.028, **p = 0.031, ***p = 0.030.
